|
|
Exchange: |
New York Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
134,770,000 |
Market
Cap: |
16.97(B) |
Last
Volume: |
873,688 |
Avg
Vol: |
1,176,928 |
52
Week Range: |
$120.62 - $146.84 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Laboratories & Research |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
|
S&P 500 |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 724 |
Guru Rank Value : 1.3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Quest Diagnostics provides diagnostic information services. Co. is made up of two businesses: Diagnostic Information Services, which develops and delivers diagnostic information services, providing insights that allow and enable a range of customers, including patients, clinicians, hospitals, independent delivery networks (including hospital health systems), health plans, employers, accountable care organizations and direct contract entities; and Diagnostic Solutions, which includes Co.'s risk assessment services business, which provides solutions for insurers, and Co.'s healthcare information technology businesses, which provides solutions for healthcare providers.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
16,337 |
16,337 |
16,337 |
534,469 |
Total Sell Value |
$2,062,619 |
$2,062,619 |
$2,062,619 |
$75,079,355 |
Total People Sold |
3 |
3 |
3 |
6 |
Total Sell Transactions |
6 |
6 |
6 |
24 |
End Date |
2024-01-18 |
2023-10-17 |
2023-04-18 |
2022-04-18 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Plewman Patrick |
SVP for Diagnostic Services |
|
2024-03-26 |
4 |
D |
$128.11 |
$14,605 |
D/D |
(114) |
15,981 |
|
- |
|
Delaney Mark E |
SVP & Chief Commercial Officer |
|
2024-03-26 |
4 |
D |
$128.11 |
$21,779 |
D/D |
(170) |
5,433 |
|
- |
|
Prevoznik Michael E |
SVP & General Counsel |
|
2024-02-29 |
4 |
AS |
$125.88 |
$706,313 |
D/D |
(5,611) |
38,478 |
|
3% |
|
Doherty Catherine T. |
EVP, Regional Businesses |
|
2024-02-29 |
4 |
AS |
$125.88 |
$149,420 |
D/D |
(1,187) |
68,412 |
|
3% |
|
Plewman Patrick |
SVP for Diagnostic Services |
|
2024-02-28 |
4 |
D |
$126.36 |
$42,078 |
D/D |
(333) |
16,082 |
|
- |
|
Gardner Mark A |
SVP of Molecular Gen & Oncol |
|
2024-02-28 |
4 |
D |
$126.36 |
$33,106 |
D/D |
(262) |
4,793 |
|
- |
|
Deppe Michael J |
SVP, Corp. Controller & CAO |
|
2024-02-28 |
4 |
D |
$126.36 |
$13,773 |
D/D |
(109) |
34,930 |
|
- |
|
Delaney Mark E |
SVP & Chief Commercial Officer |
|
2024-02-28 |
4 |
D |
$126.36 |
$28,431 |
D/D |
(225) |
5,603 |
|
- |
|
Davis J. E. |
CEO and President |
|
2024-02-28 |
4 |
D |
$126.36 |
$634,327 |
D/D |
(5,020) |
125,968 |
|
- |
|
Prevoznik Michael E |
SVP & General Counsel |
|
2024-02-28 |
4 |
D |
$126.36 |
$108,796 |
D/D |
(861) |
44,089 |
|
- |
|
Kuppusamy Karthik |
SVP, Clinical Solutions |
|
2024-02-28 |
4 |
D |
$126.36 |
$34,496 |
D/D |
(273) |
15,124 |
|
- |
|
Doherty Catherine T. |
EVP, Regional Businesses |
|
2024-02-28 |
4 |
AS |
$126.57 |
$703,349 |
D/D |
(5,557) |
69,599 |
|
2% |
|
Doherty Catherine T. |
EVP, Regional Businesses |
|
2024-02-28 |
4 |
D |
$126.36 |
$151,758 |
D/D |
(1,201) |
75,156 |
|
- |
|
Samad Samer Abdul |
Executive Vice President & CFO |
|
2024-02-28 |
4 |
D |
$126.36 |
$82,892 |
D/D |
(656) |
21,332 |
|
- |
|
Davis J. E. |
CEO and President |
|
2024-02-23 |
4 |
D |
$125.02 |
$815,756 |
D/D |
(6,525) |
130,988 |
|
- |
|
Davis J. E. |
CEO and President |
|
2024-02-23 |
4 |
A |
$125.02 |
$1,674,018 |
D/D |
13,390 |
137,513 |
|
- |
|
Doherty Catherine T. |
EVP, Regional Businesses |
|
2024-02-23 |
4 |
D |
$125.02 |
$469,700 |
D/D |
(3,757) |
76,357 |
|
- |
|
Doherty Catherine T. |
EVP, Regional Businesses |
|
2024-02-23 |
4 |
A |
$125.02 |
$1,164,436 |
D/D |
9,314 |
80,114 |
|
- |
|
Kuppusamy Karthik |
SVP, Clinical Solutions |
|
2024-02-23 |
4 |
D |
$125.02 |
$77,387 |
D/D |
(619) |
15,397 |
|
- |
|
Kuppusamy Karthik |
SVP, Clinical Solutions |
|
2024-02-23 |
4 |
A |
$125.02 |
$254,916 |
D/D |
2,039 |
16,016 |
|
- |
|
Prevoznik Michael E |
SVP & General Counsel |
|
2024-02-23 |
4 |
D |
$125.02 |
$353,182 |
D/D |
(2,825) |
44,950 |
|
- |
|
Prevoznik Michael E |
SVP & General Counsel |
|
2024-02-23 |
4 |
A |
$125.02 |
$946,276 |
D/D |
7,569 |
47,775 |
|
- |
|
Plewman Patrick |
SVP for Diagnostic Services |
|
2024-02-23 |
4 |
D |
$125.02 |
$108,642 |
D/D |
(869) |
16,415 |
|
- |
|
Plewman Patrick |
SVP for Diagnostic Services |
|
2024-02-23 |
4 |
A |
$125.02 |
$298,548 |
D/D |
2,388 |
17,284 |
|
- |
|
Deppe Michael J |
SVP, Corp. Controller & CAO |
|
2024-02-23 |
4 |
D |
$125.02 |
$78,888 |
D/D |
(631) |
35,039 |
|
- |
|
787 Records found
|
|
Page 1 of 32 |
|
|